Gearing up for the flu season
Granada – Alentia Biotech, a joint venture of Grupo Ferrer Internacional S.A. and Laboratorios Farmacéuticos Rovi S.A, has announced plans to construct a national production centre to supply the Spanish population with flu vaccines. To be built in Granada, the production plant will have an annual capacity of 10 million doses of vaccine against seasonal flu and 30 million against pandemic flu. At the end of September, Alentia also said it had signed an agreement with Novartis Vaccines & Diagnostics for the transfer and granting of a licence of use for Novartis vaccine production technology. The construction costs for the new plant are estimated at around €92m.